ERBB3 and breast cancer: Taken together, our data indicated that the miRNA cluster (miR-125a and miR-205) targeting of erbB3 significantly enhanced anti-proliferative/anti-survival effects of trastuzumab and paclitaxel on HER2-overexpressing breast cancer cells.